Generic Name and Formulations:
Sodium hyaluronate 22mg/mL; viscoelastic soln for intra-articular inj.
Indications for MONOVISC:
Treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy or simple analgesics (eg, acetaminophen).
Remove synovial fluid or effusion before inj. Give as a single intra-articular inj. 4mL in one knee only. If bilateral treatment: use one syringe in each knee.
≤21yrs: not established.
Gram (+) bacterial protein allergy. Infections or skin diseases in area of inj site/joint. Systemic bleeding disorders.
Avoid strenuous or prolonged weight-bearing activities within 48hrs following inj. Pregnancy, nursing mothers: not established.
Avoid use of disinfectants containing quaternary ammonium salts; hyaluronan can precipitate in their presence.
Arthralgia, joint swelling, inj site pain.
Single-use syringe (4mL)—1
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D